Maravai Lifesciences Acquires DNA and RNA Business from Officinae Bio
Deal News | Nov 11, 2024 | Legal Community Italy
Maravai Lifesciences, a publicly traded American company specializing in the provision of reagents and life science services for researchers and biotech innovators, has entered into an agreement to acquire the DNA and RNA business of Officinae Bio. Officinae Bio is an Italian company with a digital platform that supports the design of innovative therapeutic biological treatments. The transaction is set to close in early 2025, pending the fulfillment of certain conditions. Legal advisory for Maravai was provided by PedersoliGattai, led by Partner Gerardo Gabrielli, with a multidisciplinary team managing corporate, due diligence, antitrust, and golden power aspects. Officinae Bio was advised by Lmcr’s legal team, headed by Partner Angelo Romano.
Sectors
- Biotechnology
- Legal Services
Geography
- United States – Maravai Lifesciences, the acquiring company, is based in the United States.
- Italy – The target company, Officinae Bio, is an Italian company.
Industry
- Biotechnology – The acquisition primarily involves biotechnology as it includes the DNA and RNA business, which are critical elements in the life sciences sector for research and therapeutic innovations.
- Legal Services – Both parties in the deal are represented by legal teams from PedersoliGattai and Lmcr, highlighting the role of legal advisory in M&A transactions.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Maravai Lifesciences | Acquiring Company | Company | An American publicly traded company specializing in life science reagents and services. |
| Officinae Bio | Target Company | Company | An Italian company with a digital platform for designing biological therapies. |
| PedersoliGattai | Legal Advisor | Company | The legal firm representing Maravai Lifesciences in the acquisition. |
| Lmcr | Legal Advisor | Company | The legal firm advising Officinae Bio for the transaction. |